Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.
Isaacsohn
Jonathan L
JL
Medpace, Inc., Cincinnati, Ohio, USA. j.isaacsohn@medpace.com
Troendle
August J
AJ
Orloff
David G
DG
D003920:Diabetes Mellitus / Q000188:drug therapy; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents